Evidence map›Paper›PMID 41134802›Full record

ArticlePloS one2025

The impact of CwlM depletion on the susceptibility of Mycobacterium smegmatis to anti-tuberculosis drugs.

Shufeng Yang, Yuzhao Ren, Yu Wu, Xinyang Li, Xin Liu, Guoying Deng

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. CRISPRi-mediated silencing of the ABC transporterFrontiers in microbiology · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shufeng YangDepartment of Pathogen Biology and Microecology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Yuzhao RenDepartment of Pathogen Biology and Microecology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Yu WuDepartment of Pathogen Biology and Microecology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Xinyang LiDepartment of Pathogen Biology and Microecology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Xin LiuDepartment of Pathogen Biology and Microecology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.
Guoying DengDepartment of Pathogen Biology and Microecology, College of Basic Medical Sciences, Dalian Medical University, Dalian, China.ORCID https://orcid.org/0000-0003-1780-6708

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CwlM, identified as an N-acetylmuramoyl-l-alanine amidase, plays crucial roles in the synthesis and remodeling of peptidoglycan in mycobacteria. This protein also appears to participate in both drug susceptibility and tolerance mechanisms within these organisms. In our study, we employed CRISPR interference (CRISPRi) to deplete CwlM in Mycobacterium smegmatis (M. smegmatis) and examined the resulting effects on the susceptibility of mycobacteria to first-line anti-tuberculosis drugs, including isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB), as well as the β-lactams cefoxitin and imipenem. Our findings revealed that CwlM depletion increased the susceptibility of the bacterium to RIF, EMB, cefoxitin, and imipenem, while tolerance was heightened against INH and PZA. The enhanced antibiotic susceptibility can primarily be attributed to increased permeability of the bacterial cell wall. Conversely, the observed tolerance to INH might be ascribed to elevated expression of the amidase known as hydrazidase along with its LuxR-type regulator. Furthermore, several genes associated with peptidoglycan synthesis appeared to correlate with increased expression levels of either hydrazidase or its LuxR-type regulator. Collectively, these findings indicate that CwlM depletion significantly influences the susceptibility of M. smegmatis towards certain anti-tuberculosis drugs and may be implicated in drug susceptibility and tolerance mechanisms in M. smegmatis.

Indexed as

AmidohydrolasesAntitubercular AgentsBacterial ProteinsMycobacterium smegmatisN-Acetylmuramoyl-L-alanine AmidaseCell WallDrug Resistance, BacterialEthambutolIsoniazidMicrobial Sensitivity TestsRifampinAmidohydrolasesAntitubercular AgentsBacterial ProteinsEthambutolIsoniazidN-Acetylmuramoyl-L-alanine AmidaseRifampin

Identifiers

PMID41134802
PMCPMC12551912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.